Category Archives: Industry: Healthcare

Healthcare is an ever evolving industry, and field. These Press Releases, will keep you up to date on the newest, greatest, best, solutions available.

Industry: Healthcare

Race for Relapsing Polychondritis’ Drive for Awareness Makes a Stop in Marquette this Week for A Symposium Exploring Autoimmune Diseases

Leave a comment


News Image


MARQUETTE, Mich. (PRWEB)

If you are one of the 50 million Americans who live with an autoimmune disease, you know that it can be challenging to get the answers you need. If you’re a medical professional, you know that educational resources about these diseases are limited. Whether it’s lupus, rheumatoid arthritis, relapsing polychondritis or one of the many other autoimmune diseases, not nearly enough is known about diagnosis and treatment.

NMU’s Doctor of Nursing Practice Program, in conjunction with the Race for RP (Relapsing Polychondritis) present A Symposium Exploring Autoimmune Diseases, Friday, September 20, at Reynolds Recital Hall. This half-day session is free and open to the public. Experts will discuss the latest research, treatments and best practices for those living with an autoimmune disease. If you or someone you know have been diagnosed with an autoimmune disease, this is a rare opportunity to hear directly from leaders in the field. If you are a medical professional, you can earn continuing medical educational credits.

“One of our main priorities at Race for RP is to make sure those impacted by these diseases have access to the latest information and best practices. This collaboration with the School of Nursing at NMU is a perfect opportunity to team up and increase awareness,” said David Bammert, President of the RP Foundation. “Health care professionals, nursing students and community members who may be living with these diseases will be able to engage with autoimmune specialists directly,” he added.

Featured speakers include Dr. Susan Manzi, Chair of the Allegheny Health Network Medicine Institute and Chair of the Lupus Foundation of America National Board of Directors; Dr. Joseph M. Ahearn, Chair of the Allegheny Health Network Autoimmunity Institute; and Dr. Emily Somers, specialist in epidemiology at the University of Michigan Schools of Medicine and Public Health.

A Symposium Exploring Autoimmune Diseases takes place Friday, September 20, 12:30 p.m. – 4:00 p.m. at Reynolds Recital Hall at NMU. This event is free and open to the public. For additional information visit, http://www.bit.ly/AutoimmunitySymposium

About Race for RP

Race for RP supports research, awareness programs, and quality care for those who are affected by relapsing polychondritis and related diseases. The Race for RP is driving awareness and accelerating research. For more information visit, http://www.raceforrp.org

About Relapsing Polychondritis Foundation

The Relapsing Polychondritis Foundation’s purpose is to increase awareness about relapsing polychondritis (RP), provide for those who are affected by RP, support research to advance a cure, and promote quality care for RP patients. For more information visit, http://www.polychondritis.org

About Relapsing Polychondritis

Relapsing polychondritis (RP) is rare, debilitating and in some cases fatal autoimmune diseases which attacks the patient’s cartilage including the ears, nose, airways and joints, as well as the eyes, skin, heart valves and brain.

Share article on social media or email:

Industry: Healthcare

Henry Ford e-Home Care Reduces Hospital Readmissions Utilizing Telehealth from HRS

Leave a comment


Utilizing technology to care for our patients is the future of healthcare. Technology provides access to patients in more ways that are convenient for them.


DETROIT (PRWEB)

Henry Ford e-Home Care has announced a significant reduction in hospital readmissions for patients receiving telehealth care via Henry Ford’s e-Home Care program. Achieving monthly readmission rates as low as 7%, Henry Ford e-Home Care has reduced their average hospital readmission rate for the first six months of 2019 by 45% compared with the prior six months of 2018. Utilizing software from Health Recovery Solutions (HRS), Henry Ford e-Home Care provides remote patient monitoring and telehealth services to more than 130 patients each month.

Henry Ford e-Home Care partnered with HRS in 2017 to capitalize on the growing role of technology in healthcare and its ability to help improve clinical outcomes and reduce costs to health systems, payors, and patients. Through its e-Home Care program, Henry Ford is able to treat a diverse set of patient populations, including those with chronic CHF, COPD, hypertension, and cancer, as well as patients recovering from cardiothoracic or transplant surgery.

“Utilizing technology to care for our patients is the future of healthcare. Technology provides access to patients in more ways that are convenient for them, efficient for care providers, and offers an extra layer of safety for our patients in their homes,” said Mary Hagen, Manager of Henry Ford e-Home Care. “We see a future in which patients are comfortable with and proficient at utilizing mobile devices to communicate with clinicians, manage their healthcare, and be more knowledgeable about their own health, as well as the health of their loved ones.”

Patients are enrolled in e-Home Care following an initial home health visit. Once enrolled, patients receive a 4G tablet pre-loaded with the HRS software, along with Bluetooth biometric monitoring devices. Via the tablet, patients receive medication reminders, access educational videos and daily disease-specific symptom questions, and record daily vitals utilizing the biometric devices. In addition, patients and clinicians can utilize phone calls and a video conferencing platform on the tablet. All patient data is uploaded in real-time to the clinician’s dashboard and the Health System EMR, allowing a patient’s entire care team to observe the patient’s health status.

Using the clinician dashboard, phone conversations, and virtual visits, Henry Ford’s telehealth nurses address variances in patients’ vitals. Patient data from the telehealth and remote monitoring system enable the telehealth team to observe trends in patient status, adherence, and self-care, to quickly intervene when a patient’s status puts them at risk for readmission.

“Henry Ford’s e-Home Care program demonstrates the importance of communication across the care continuum. Their EMR integration and centralized care model are key drivers of their program’s success and prove their dedication to patient care and innovation. We are excited to continue working with Henry Ford to expand their telehealth program and access to care,” added William Ashton, Client Success Manager at HRS.

In the coming months, Henry Ford e-Home Care will look to expand their program by partnering with insurance agencies to further reduce the cost of care and incorporate more patients into their comprehensive care continuum.

About Henry Ford e-Home Care

A part of Henry Ford at Home, Henry Ford e-Home Care provides technology in patients’ homes to keep them safe, prevent unnecessary hospitalizations, and assist caregivers in caring for their loved ones. Partnering with top-rated vendors to offer technology solutions to Detroit and its surrounding communities, it is strategically situated within the Henry Ford Health System to support the System’s population health focus as they transition patients to home. As Henry Ford at Home’s technology division, e-Home Care educates and advocates for patients and their families while utilizing the features of innovative technology to prevent exacerbations of chronic diseases which often lead to ED visits and possible rehospitalizations. To learn more about Henry Ford e-Home Care, visit https://www.henryford.com/services/at-home.

About Health Recovery Solutions

Health Recovery Solutions (HRS) supplies leading health systems with the most advanced remote monitoring platform and technology-enabled management services focused on changing patient behavior to reduce readmissions and improve clinical outcomes. HRS’ disease-specific telehealth solutions are customized with educational videos, care plans, and medication reminders while also integrated with Bluetooth peripherals to engage patients. For clinicians, HRS’ software allows for the management of high-risk patients and provides seamless communication with them through video chat, wound imaging, and text messaging. For family members and caregivers, HRS’ software gives them the ability to be fully involved in their family member’s care and well-being. To learn more about Health Recovery Solutions, visit https://www.healthrecoverysolutions.com/ or call (347) 699-6477.

Share article on social media or email:

Industry: Healthcare

Anelto Health has announced its “Partnership for Better Outcomes” by releasing its new “No-Risk RPM Platform” for Remote Patient Monitoring

Leave a comment


“We have removed all the barriers associated with organizations that are unfamiliar with buying or leasing equipment”, said David Fronk, SVP of Business Development and Sales at Anelto Health


THE COLONY, Texas (PRWEB)

Anelto Health, has launched its new “No-Risk RPM Platform for Remote Patient Monitoring. The platform can integrate with software systems for Chronic Care Management, CCM, Care Management, CM, or Transitional Care Management, TCM. In conjunction with TCM, CCM or Care Management, the 2-way dynamic voice hub pairs with vital sign monitors and activity trackers to improve the health of the senior and to prevent unnecessary ER visits and hospitalizations. It has built in alerts and dynamic, intuitive patient reactive questionnaires and ability to integrate with a 24/7 clinical call center. Anelto’s No-Risk RPM Platform eliminates the risk associated with owning and deploying hardware-based systems.

“We have removed all the barriers associated with organizations that are unfamiliar with buying or leasing equipment”, said David Fronk, SVP of Business Development and Sales at Anelto Health. “Hospitals and companies that want to implement an RPM solution for better care and outcomes for their patients can now move forward with confidence. If they can’t bill for the equipment, by using the existing CPT 99454 for RPM, there is no monthly equipment charge from Anelto. Anelto Health is determined to make sure our equipment does what it was designed to do, and that is to improve communication with the patient, engage them in their health and get them to take their vital signs daily so the data and the analytics can help improve the patient’s life by improving their chronic diseases.”

RPM is a new efficient way of caring for seniors outside of their doctor’s office that can reduce the cost associated with caring for this subset of the population while dramatically improving clinical outcomes and their quality of life. This allows them to “age in place”, which over 80% of seniors prefer. We believe with CPT code 99454, that the economic benefits for CCM companies or hospitals make this a win-win for the patient and those providing services to the patient.

Additional benefits of Anelto Health’s Remote Patient Monitoring System include:


  • Easy to set up and use.

  • Always on with a 3-day emergency battery pack for times when power is out.

  • Comes with a friends and family app to keep up with your loved one. Know how they are doing on their chronic disease care, activity and allows for communication and encouragement.

  • Fun activities and communications to keep the senior engaged and help with depression from loneliness

  • Programmable call functionality to allow a 24/7 call center integration or their doctor or his/her care team to call into the hub relieving the stress of answering the phone of an unknown caller.


To make an appointment for a meeting at the upcoming HIMSS Health 2.0 Conference in Santa Clara, CA on 9/16 – 9/18/2019 or to know more about Anelto Health, it’s Remote Patient Monitoring Platform, request a white paper or clinical paper: Visit its website at https://www.aneltohealth.com and also view the patient interactive video on Anelto Health’s unique platform.

Share article on social media or email:

Industry: Healthcare

A ‘New Dawn’ in Treating Early Osteoarthritis of the Basal Joint

Leave a comment


https://www.prweb.com/

Dr. Alejandro Badia

Until now, effective treatments for stopping the progression of osteoarthritis have been limited but increasing studies of the biological basis of the disorder are leading to new therapies, including application of protease inhibitors.


MIAMI (PRWEB)

Scientists writing in a 2017 issue of European Medical Journal predicted that new, more effective therapeutic agents to stop the progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” Well, that day may already have dawned, says Miami-based hand and upper limb orthopedic surgeon Alejandro Badia, MD, founder and chief medical officer of the Badia Hand to Shoulder Center and OrthoNOW®, who is using advanced techniques, including natural biomaterials, to treat osteoarthritis of the thumb.

An expert in orthobiologics, Dr. Badia is harnessing the power of protease inhibitors to slow, and potentially halt, destruction of joint cartilage in the basal — carpometacarpal (CMC) – joint at the base of the thumb in patients with early osteoarthritis of the hand.

Orthobiologics involves utilizing a patient’s own biologic substances, or those of a donor, including blood platelets (PRP therapy) and adult (mesenchymal) stem cells, to mitigate inflammation, relieve chronic musculoskeletal pain and repair orthopedic injuries.

Dr. Badia explains that inflammation is a response to age-related wear-and-tear or injury to a joint and is believed to support the transition to pathological osteoarthritis. Although many factors can contribute to the development of osteoarthritis, nobody knows the primary cause of the debilitating disease. Many sedentary people develop this as they age, and both occupational and genetic factors play a part. It is certain however that repetitive and acute injuries, if untreated, will worsen the symptoms of underlying arthritis and accelerate its development and progression.

Researchers have determined that cartilage degradation is accelerated by chronic inflammation through the excessive activity of proteases, enzymes that normally function to clear damaged tissue after an injury but when they persist in chronically-inflamed joints they lead to degradation of cartilage and subsequent joint pain. Cartilage serves as a cushion for joints; its breakdown leads to joint stiffness and pain, Dr. Badia explains. Proteases are vital to many biological functions, such as digestion and cellular repair, but over-activity of these enzymes in the joint can speed the degradation of cartilage’s extracellular matrix.

But, protease inhibitors, like alpha 1-antitrypsin and alpha 2-macroglobulin, are molecules that can be harvested from blood plasma and other tissues to inhibit inflammatory proteases and clear them from the joint.

“Injection of these inhibitors into the basal joint is proving successful in some patients for relieving the debilitating pain of osteoarthritis of the thumb and potentially helping rebuild some of the lost cartilage,” says Dr. Badia. He and his team at OrthoNOW have treated arthritic patients using a variety of advanced surgical, non-surgical and orthobiologic approaches.

Osteoarthritis is the most common joint disease overall. Basal joint osteoarthritis, a specific form of the disorder, is the second most common arthritic condition of the hand, Dr. Badia says. The thumb disorder can result in severe pain, loss of grip function, strength and restricted range of motion and even deformity – to the point where a patient has difficulty holding a can or glass, opening a jar lid or buttoning a shirt, Dr. Badia notes.

Until now, effective treatments for stopping the progression of osteoarthritis have been limited but increasing studies of the biological basis of the disorder are leading to new therapies, including application of protease inhibitors.

Dr. Badia credits scientists like Shawn Browning Ph.D., vice president of research and development at Holding Technologies, who has studied the biology of joint cartilage degeneration in osteoarthritis, and medical innovators, such as Ziad Hamandi, chief executive officer of ABT Medical, for progress in treating osteoarthritis with protease inhibitors and other orthobiologics. Under Hamandi’s leadership, ABT Medical and their physician collaborators have designed advanced processes for separating blood and other fluid biologics into needed therapeutic components.

“The mission ABT Medical is to be innovative in the development of comprehensive blood management programs that are both responsive and reliable,” Hamandi states.

Orthobiologic therapies are not without risk, according to the federal Food and Drug Administration (FDA). Side effects can include reactions at site of injection, failure of biomaterials to perform as intended, and migration of injected cells away from treatment areas, potentially changing into unwanted cell types, multiplying, and negatively affecting other tissues.

Dr. Badia advises caregivers to exercise caution when administering biomaterials and exhorts patients to be especially careful when seeking medical help in the area of orthobiologics, a specialization in which practitioners often lack necessary training and expertise. It is imperative for patients who are considering regenerative medicine options to seek a clinician who can offer multiple remedies and solutions depending on the patient’s needs and stage of disease. In many cases, clinicians who have stem cell clinics are limited in what they can offer. OrthoNOW provides autologous access to stem cell therapies as well as other conservative therapies that the patient may benefit from, including anti-inflammatory mediators, physical therapy, procedures such as a joint arthroscopy, or even joint replacement for more severe cases. Dr. Badia worries that sometimes patients are being misled by practitioners who are not fully qualified to do regenerative medicine.

“Better than the best therapies for osteoarthritis, of course, is prevention,” states Dr. Badia. “You cannot stop joints from growing older, but you can reduce your risk for joint problems.” He offers the following recommendations:

  • Maintain an appropriate weight.

  • Keep joints heathy through exercise.

  • Control blood sugar.

  • Avoid joint injuries by wearing the proper protective gear when engaged in sports.

See an orthopedic specialist as soon as possible for diagnosis and treatment if a joint injury fails to heal. Injured joints are seven times more likely to develop osteoarthritis, according to the Arthritis Foundation.

Bio: Alejandro Badia, MD, FACS, internationally renowned hand and upper-limb surgeon and founder of Badia Hand to Shoulder Center and OrthoNOW®, a walk-in orthopedic care clinic. He is a member the American Society for Surgery of the Hand, American Association for Hand Surgery, and the American Academy of Orthopedic Surgeons. He is a specialist in treating all problems related to the hand and upper extremity including trauma, sports injury, joint reconstruction, nerve injuries and arthroscopic surgeries. OrthoNOWcare.com and drbadia.com.

Industry: Healthcare

Navigating Cancer, the Leader in Oncology Patient Relationship Management, Receives $26 Million in Oversubscribed New Funding

Leave a comment



SEATTLE (PRWEB)

Navigating Cancer (NC), the leader in enabling personalized cancer care with its comprehensive oncology patient relationship management solution, announced today that it has received $26 million in Series D growth equity funding in an over-subscribed round led by the Merck Global Health Innovation Fund (GHIF) and TT Capital Partners (TTCP). The company’s end-to-end software platform, adopted by more than 1,700 cancer care providers domestically, uniquely connects providers and their patients throughout the care cycle.

Other investors in the round include BrightEdge, the American Cancer Society’s newly formed philanthropic venture fund; LabCorp®; ORIX Growth Capital; and Rustic Canyon Partners.

The funding will enable NC to accelerate innovation of its Patient Relationship Management (PRM) platform, including delivery of a more robust mobile experience for oncology patients and the development of NC’s AI-based population care capabilities. With NC’s platform, oncology practices are able to increase patient engagement, create a more responsive experience for cancer patients, and ultimately improve overall cancer care.

Forty Percent Growth Predicted in 2019

For 2019, Navigating Cancer is on pace to grow its oncology customer base by 40 percent. Accelerating adoption of NC’s unique platform is enabling more practices to succeed in delivering value-based care, a model that pays hospitals and physicians based on patient outcomes as opposed to fixed fees based on the service provided.

Navigating Cancer’s PRM platform helps providers manage patient interactions, improve the patient experience, and deliver value-based care more effectively – increasing the flow of communications between in-office visits, which, in turn, boosts patient engagement in their own care. NC’s platform also helps providers contain escalating costs. According to a study published in the Journal of Oncology Practice, two community cancer centers utilizing NC’s PRM platform generated significant cost savings due to better symptom management, while reducing emergency room visits by seven percent.

“This investment from these leading healthcare organizations really affirms the work that Navigating Cancer is doing to improve patient care and the success we’re seeing in helping oncology providers make the shift to value,” said Bill Bunker, the CEO of Navigating Cancer. “I’m excited about the innovations we’re making in areas like patient-reported outcomes and population care and the potential they have to further improve patient outcomes and satisfaction.”

“Oncologists must care for patients in an extremely complex regulatory and reimbursement environment, while managing a rapidly expanding number of therapy choices and effects across indications,” said David M. Rubin, Ph.D., Managing Director of Merck GHIF. “We’re delighted to continue our investment in this comprehensive patient care platform.”

Specifically, patients using the PRM platform can send messages to their doctor, receive reminders to take their medications, and report symptoms via a mobile app. Care providers, meanwhile, can triage patient needs; assess and manage symptoms and side effects; and streamline communications and care coordination for quicker responses.

Going forward, innovation in the PRM platform will incorporate artificial intelligence to support the assessment of patients at risk for various issues and identify proactive interventions to help improve care.

“More and more oncology practices are picking up the NC oncology platform because it’s a superb example of the heightened effectiveness created by leveraging 21st century technology in the practice of medicine,” said Bob Crutchfield, managing director of BrightEdge, the philanthropic impact fund of the American Cancer Society.

“As the dynamics of how providers, patients, and caregivers interact with one another continue to change in healthcare, Navigating Cancer’s platform represents a powerful example of technology enhancing the delivery of care and improving the overall healthcare experience,” said Tim Scallen, Principal at TT Capital Partners. “We look forward to collaborating with the management team to further extend Navigating Cancer’s platform reach and enhance the benefits it delivers to all cancer patients and providers.”

About Navigating Cancer

Navigating Cancer is the leading Patient Relationship Management technology and solutions company focused on improving the patient experience, delivering more effective care management and enabling oncology care innovation. With over 1,700 providers adopting the Navigating Care platform, it is the most broadly deployed patient management solution in oncology. The company’s products combine clinical workflows, oncology content and data insights to empower personalized care for cancer patients inside and outside of the clinic. For more information, please visit http://www.navigatingcancer.com or follow Navigating Cancer on Twitter @navcancer.

About TT Capital Partners

TT Capital Partners (TTCP) is a healthcare investor, collaborating with healthcare technology and services companies that have the potential to become market leaders. Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth healthcare businesses. TTCP is part of the TripleTree healthcare merchant bank. For more information, visit TTCapitalPartners.com.

About BrightEdge

BrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. The fund is led by a board comprised of the Society’s leaders and a management team with expertise in investment and venture capital. BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapies and technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer. https://brightedgefund.org/.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenues of more than $11 billion in 2018. To learn more about LabCorp, visit http://www.LabCorp.com, and to learn more about Covance Drug Development, visit http://www.Covance.com.

Industry: Healthcare

Access Healthcare Appoints Jessica Cooley as Chief Marketing Officer

Leave a comment


Jessica Cooley, Chief Marketing Officer, Access Healthcare

Jessica Cooley, CMO, Access Healthcare

The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.


DALLAS (PRWEB)

Access Healthcare, one of the largest providers of healthcare revenue cycle management and IT services, today announced that Jessica Cooley has been appointed to the company’s executive leadership team as Chief Marketing Officer. In her new role, Cooley will spearhead the company’s global branding and marketing initiatives enabling the customer-facing sales efforts and building the teams towards executing the company’s strategic vision.

Cooley brings more than 17 years of experience in the healthcare industry and has a track record of generating significant profit, enhancing corporate credibility, and increasing market penetration. Prior to Access Healthcare, she was the Vice President of Strategic Accounts & Implementation for Provista, a Vizient subsidiary. While at Provista, she created and led the organization’s Strategic Accounts business unit, which now operates over $91 million in revenue responsibility. Cooley was instrumental in the ambulatory strategy development and execution as part of Provista’s long term growth plan. Cooley has earned several honors including President’s Circle 2016, Sales Excellence 2010, and Exceeding Excellence for 2003 and 2008.

“We are happy to welcome Jessica to our executive leadership team. Over the last few months, we’ve been focusing on building a strategy for how sales and marketing functions to enable the next phase of company’s growth,” says David Tassoni, President of US Operations of Access Healthcare. “We have been growing exponentially and Jessica’s deep marketing experience and strong business insights will bring significant opportunities for Access Healthcare and our business teams as we continue to move forward.”

“Access Healthcare is one of those brands that is revolutionizing the healthcare industry, and I’m truly excited to be part of this growing company,” says Cooley. “The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.”

Cooley holds a B.S. in Human Development from Texas Tech University and is an active member of organizations such as the Young Men’s Service League, Professional Women in Healthcare, and the National Charity League.

About Access Healthcare

Access Healthcare provides business process outsourcing, applications services, and robotic process automation tools to healthcare providers, payers, and related service providers. The company operates from 19 delivery centers in the US, India and the Philippines, and its 12,000+ staff is committed to delivering revenue cycle excellence by leveraging technology, emerging best practices, and global delivery. Based in Dallas, Access Healthcare supports over 300,000 physicians, serves 80+ specialties, processes over $70 billion of A/R annually, and ascribes medical codes to over 30 million charts annually. To learn more, please visit http://www.accesshealthcare.com.

Share article on social media or email:

Industry: Healthcare

CLM Value Leader SirionLabs Announces 2019 Customer Advisory Board Event to Showcase Technology Innovations and Industry Trends

Leave a comment


News Image

This year, we’re honored to be joined by market-leading corporations from a wide range of industries – financial services, energy, pharmaceuticals, telecom, food & beverage – who all believe that CLM has become fundamental to business transformation.


NEW YORK (PRWEB)

SirionLabs, the leader in contract lifecycle management (CLM) technology designed to enhance value across the full lifecycle of enterprise contracts, today announced that the company’s annual Customer Advisory Board (CAB) event will be held in Chicago on Sept. 17-18, 2019. This year’s event goes further than ever before in showcasing presentations on digital transformation initiatives, unveiling the company’s technology roadmap and bringing together industry luminaries to explore ongoing trends and future scenarios. SirionLabs CAB represents an engaged group that includes senior procurement, legal and business executives from SirionLabs customers such as BP, Vodafone, Credit Suisse, Greater Toronto Airports Authority (GTAA), Fujitsu, Optus and Unilever. And for the first time, SirionLabs has invited a select group of companies outside its customer base to offer their perspective on this critical discipline and the technologies now reaching the market.

“As our Sirion community continues to blossom with each passing year, we look forward to this annual opportunity to meet in person, celebrate our joint successes, and set our collective agenda for the year ahead,” said Ajay Agrawal, Chairman and CEO of SirionLabs. “On behalf of all my SirionLabs colleagues, I warmly welcome our existing community, our prospective customers, and our partners to this very special get-together. This year, we’re honored to be joined by market-leading corporations from a wide range of industries – financial services, energy, pharmaceuticals, telecom, food & beverage – who all believe that CLM has become fundamental to business transformation. Sirion technology is purpose-built to play a critical role in this transformation, and we’re excited to learn more from the innovators attending this event.”

Key highlights from the agenda include:

Also on the agenda is “CLM 2020 and Beyond,” a webinar designed to explore key developments driving CLM as a foundational technology for the modern enterprise. The webinar will analyze trends accelerating this evolution, including the changing role of the Chief Procurement Officer; the Uberization of the supply chain; CLM data science; reverse contracting; and ‘smart’ contracts. The panel for the discussion includes Shanti Berggren, Deputy General Counsel, Optus; Liz Evans, Principal, KPMG; Tim Cummins, President, IACCM; and Claude Marais, Co-founder and President, SirionLabs.

ABOUT SIRIONLABS

SirionLabs transforms enterprise engagements by bringing buyers and suppliers closer together across the full lifecycle of the contract, from authoring to performance to closure. Sirion’s award-winning CLM platform serves as a single source of truth for both parties across all key disciplines: contract authoring and management, performance management, invoice validation and buyer-supplier collaboration. This holistic approach materially reduces friction between parties, improves transparency and trust, and drives improved outcomes and tangible savings while reducing the cost of governance.

Learn more about us at http://www.sirionlabs.com.

Media Contact:

Devinder Jeet Singh

GM – Marketing

media.relations(at)sirionlabs.com

Share article on social media or email:

Industry: Healthcare

Medrio eClinical Rolls Out New CRO Resource Portal Designed to Empower CROs and Nurture Sponsor Relationships

Leave a comment


News Image

“Medrio’s CRO Portal contains extremely helpful information for capabilities and bid defense meetings. The one-pagers and sales decks are easily integrated into our company presentations and provide just the right amount of information without too much detail”


SAN FRANCISCO (PRWEB)

Medrio, a leading provider of eClinical technology for pharma, medical device, and diagnostics companies conducting clinical trials, today announced the launch of a new resource portal designed to empower CROs and consultants to develop and nurture sponsor relationships.

Medrio’s CRO Resource Portal equips CROs and consultants for success with leading support, training, and self-service tools. Medrio’s enhanced support of CROs is a collaborative effort aligning Medrio’s sales, marketing, product, and development resources with trusted CROs and consultancies to deliver superior customer experiences.

The Medrio CRO Resource Portal provides partners with outstanding resources to rise above the competition, deliver greater sponsor satisfaction, and grow their business. As digital technology continues to disrupt clinical trials and as more sponsors choose to outsource to CROs, channel partners are turning to Medrio for proven solutions that quickly integrate into clinical workflows, facilitate research, and deliver high value to study Sponsors.

Medro’s new CRO Resource Portal provides partners with on-demand sales growth tools, marketing resources, and top-tier training for success in the rapidly-changing clinical research landscape:


  • Win more sponsor bids: Increase competitiveness by accelerating research timelines and lowering clinical trial costs.

  • Boost sales and relationships: Discover new sales opportunities and grow existing relationships with a comprehensive resource center, sales assets, video testimonials, product demos, and co-marketing opportunities.

  • Stay ahead of the competition: Access exclusive learning and development opportunities, including information on the latest industry developments.

“Medrio’s CRO Portal contains extremely helpful information for capabilities and bid defense meetings. The one-pagers and sales decks are easily integrated into our company presentations and provide just the right amount of information without too much detail”.

Deborah Bates, MA, CCRP, Clinical Project Manager, Tranquil Clinical Research

Share article on social media or email:

Industry: Healthcare

Spoke Health Selected for Launch Health Accelerator Powered by Nueterra Capital

Leave a comment



DENVER (PRWEB)

Spoke Health, a healthcare marketplace solution that tackles high cost care episodes for value-based programs, has been selected to join the Launch Health Accelerator powered by Nueterra Capital. The accelerator is designed for early-stage businesses deemed likely to disrupt and improve the current healthcare system. Along with 5 other companies, Spoke Health will receive an equity award as well as a 75-day boot camp of collaboration and development with Nueterra Capital and program supporters in Kansas City (https://www.nueterra.com/nueterra-capital-accelerator-selects-cohort/).

“We have been introduced to several accelerator programs and the Launch Health Accelerator is one of the most comprehensive programs for businesses like Spoke Health that are working to disrupt the current healthcare system. We are proud to be working with a team that shares Spoke Health’s mission and vision to build powerful technology solutions that make the healthcare system work better and create healthier consumers. We are impressed with the amount of time and resources Nueterra Capital is investing to accelerate our business” said Linda Bernier, CEO at Spoke Health.

Spoke Health’s unique position to create a transparent, efficient and engaging marketplace for high quality, low cost care episodes leverages the company’s roots in global medical tourism. The company’s founders built the core technology platform after experiencing high quality healthcare abroad from hospitals offering pre-packaged, bundled care services, transparent costs, cash pay and open market competition. In 2016 Spoke Health was launched in the US market to address the unsustainable healthcare cost crisis and the demand for new care and payment models by employers, who cover over 150 million people.

“We started with the $700B surgery market, which represents the largest healthcare spend category for employers and their biggest opportunity to cut costs, in some cases by 50%,” said Jason Coppage, Spoke Health’s co-founder and Chief Product Officer. “Our software went live in April and is being used by our partners and a large health system to engage employees toward better outcomes for expensive hip and knee surgeries. The technology automates the entire episode experience and offers robust workflow along with ‘high tech and high touch’ consumer interactions. In fact, early results for the nearly 30 patients and 26 care advocate and concierge users leveraging the platform demonstrate a 10x increase in touchpoints to better engage employees in their care episode, resulting in reduced complications and greater overall satisfaction.”

“Spoke Health’s platform helps health systems, TPAs, payers and other benefits providers package and automate value-based programs at scale for their employer clients.The solution includes three main capabilities: robust digital consumer tools, care and concierge workflow and dashboards, and provider contract administration capabilities that efficiently display and manage componentized costs for bundled contracts ,” said Greg Mogab, Spoke Health’s co-founder and Chief Technology Officer. “We wake up every day highly motivated to build powerful, easy-to-use SaaS technology that takes the hassle out of the US healthcare system and creates great consumer experiences even during a stressful care event.”

About Spoke Health

Spoke Health partners with healthcare organizations to deploy and scale new care and payment models to tackle high cost care episodes from “ouch to outcome” while offering high tech and high touch customer service. The Spoke Health platform is the connected ecosystem hub built specifically to power value-based programs and create healthcare marketplaces that integrate and automate the full episode of care experience for consumers, concierge and care advocates. Launched in 2016 and headquartered in Denver, Colorado, Spoke Health is led by Chief Executive Officer Linda Bernier and co-founders Jason Coppage and Greg Mogab.

For more information go to http://www.spokehealth.com or contact Linda Bernier, CEO at Spoke Health at Linda@Spokehealth.com.

Share article on social media or email:

Industry: Healthcare

Mario Lemieux Foundation, Highmark Health Establish Research Fund in the Division of Cardiac Electrophysiology at Allegheny Health Network

Leave a comment


“Our Foundation is committed to supporting important research and patient care, and we are pleased to give this gift that will help so many people in our community,” said Lemieux.


PITTSBURGH (PRWEB)

Commitment of $2 million aims to advance leading-edge care for patients with atrial fibrillation and other heart rhythm disorders

PITTSBURGH, Pa (September 16, 2019) – Representatives from the Mario Lemieux Foundation today joined Highmark Health and Allegheny Health Network (AHN) officials to announce a major investment in the health of patients with heart rhythm disorders. A $1 million gift from the Mario Lemieux Foundation, with matching funds from Highmark Health, will establish The Mario Lemieux Innovation and Research Fund in the Division of Cardiac Electrophysiology (EP) at AHN’s Cardiovascular Institute.

The $2 million investment by the Foundation and Highmark Health will support medical research and the development of innovative therapies and technologies for heart rhythm disorders, a cause close to the heart of Mario Lemieux, Foundation chairman, NHL Hall of Famer and Pittsburgh Penguins owner.

“Our Foundation is committed to supporting important research and patient care, and we are pleased to give this gift that will help so many people in our community,” said Lemieux.

Lemieux was diagnosed with a heart rhythm disorder called atrial fibrillation (Afib) in 2005 and guides his foundation by supporting important patient care and research in the region. The Foundation’s gift to AHN is its first to an adult cardiovascular program.

“Our mission is to create programs that improve the lives of western Pennsylvanians and to collaborate with organizations who share that commitment,” said Tom Grealish, president of the Mario Lemieux Foundation. “Allegheny Health Network’s Cardiovascular Institute is nationally recognized for its expertise in the treatment of heart and vascular disease, and we are excited to help further enhance its capabilities in the specialized care of heart rhythm disorders.”

In the United States, Afib is the most common heart rhythm disorder affecting more than six million people. The condition occurs when the two upper chambers of the heart quiver out of sync with the lower chambers causing less blood to be circulated throughout the body, elevating a patient’s risk of heart failure and stroke.

The funding from the Foundation and Highmark Health will help further establish AHN’s EP program as a center for innovative research into the cause and treatment of heart rhythm disorders with a particular focus on minimally invasive therapies for Afib. The funds will also support the use of advanced data systems to develop predictive algorithms that promote more efficient and effective care pathways for patients with cardiac arrhythmias.

“At Highmark Health, we take great pride in our legacy of service to the western Pennsylvania community and one of the key elements of our success through the years has been the many opportunities we have had to work with outstanding organizations like the Mario Lemieux Foundation to make our communities better, healthier places to live,” said David Holmberg, president and CEO of Highmark Health. “Together with the Foundation, we are extremely excited to establish the framework of a game changing program that will help mend and strengthen the hearts of our members and patients today, and well into the future.”

AHN’s flagship Allegheny General Hospital (AGH) is a leading referral center in Western Pennsylvania for advanced cardiovascular care and cardiovascular research, including clinical trials of new medications and technologies available only at the most specialized medical centers in the country. AHN’s community hospitals also have some of the best cardiovascular programs in the region with cardiologists and cardiothoracic surgeons who have led the way in transforming community-based cardiovascular care.

“We are immensely grateful to the Mario Lemieux Foundation and to Highmark Health for their generous support of our Cardiovascular Institute, their recognition of the quality and capabilities of our clinicians, their understanding of the importance of research and their confidence in our vision for transforming the treatment of heart rhythm disorders and other diseases of the heart and vascular system,” said Allie Quick, chief philanthropy officer at Allegheny Health Network.

AHN’s EP program has long been at the forefront of innovative techniques and technologies for treating heart rhythm disorders and similar heart conditions. Led by Amit Thosani, MD, director of the Cardiac Electrophysiology Division, the program was the first in the region to perform zero fluoroscopy ablation to treat Afib and other heart rhythm abnormalities, greatly improving the safety of a common procedure that uses radiofrequency energy to stabilize an irregular heartbeat. In collaboration with the Network’s advanced heart failure and cardiac surgery teams, the EP program was also a first in the region to perform mapping and ablation of ventricular tachycardia at the time of open heart surgery.

“As the U.S. population continues to age, the number of those diagnosed with atrial fibrillation is expected to increase to 12 million by 2030 so it’s important that our multidisciplinary cardiac teams continue to deliver treatments that improve outcomes and bring world-class care to our patients, close to home,” said Srinivas Murali, MD, chairman of the Department of Cardiovascular Medicine at Allegheny Health Network. “Thanks to the vision and generosity of organizations like the Mario Lemieux Foundation, our team can only further advance the development and implementation of more innovative diagnostic and minimally invasive solutions which benefit patients.”

Other faculty of the Division of Cardiac Electrophysiology who will play a role in work supported by fund include William Belden, MD, Chris Bonnet, MD, John Chenarides, MD, Mati Friehling, MD, Emerson Liu, MD, and George Shaw, MD.

“Exceptional clinical care and pioneering expertise in the study and treatment of complex cardiovascular diseases has been a hallmark of our Network, and its hospitals, for more than a century,” said George Magovern, MD, chair, AHN Cardiovascular Institute. “Patients with heart rhythm disorders in particular can be assured that the scope of resources available to them at Allegheny Health Network is second to none.”

About the Allegheny Health Network:

Allegheny Health Network (AHN.org), a Highmark Health company, is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of eight hospitals, including Allegheny General Hospital, its flagship academic medical center in Pittsburgh, Allegheny Valley Hospital in Natrona Heights, Canonsburg Hospital in Canonsburg, Forbes Hospital in Monroeville, Jefferson Hospital in Jefferson Hills, Saint Vincent Hospital in Erie, West Penn Hospital in Pittsburgh and Westfield Memorial Hospital in Westfield, NY. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, cardiovascular disease, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes and more. It also is home to a comprehensive research institute; Health + Wellness Pavilions; an employed physician organization, home and community based health services and a group purchasing organization. The Network employs approximately 21,000 people, has more than 2,400 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine, Temple University School of Medicine, and the Lake Erie College of Osteopathic Medicine.

About the Mario Lemieux Foundation

The Mario Lemieux Foundation is a 501 (c) 3 organization that raises funds for cancer research and patient care, as well as Austin’s Playrooms, an initiative that creates playrooms for children and families in medical facilities. http://www.mariolemieux.org.